Blackstone launches cardio-focused biopharma with Novartis

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/magicmine)
(Image: Getty/magicmine)

Related tags: Novartis, cardiovascular disease, Blackstone group, Biopharmaceutical, Stroke

Blackstone launches Anthos Therapeutics, with the help of Novartis, to develop targeted therapies for cardiovascular disease.

Anthos was launched after Blackstone Life Sciences, a private investment platform, provided $250m (€219.6m) in capital and Novartis agreed to license an anti-thrombotic treatment candidate.

Blackstone will control the development of Anthos’ while Novartis will retain a minority equity interest in the new biopharma company.

Anthos has licensed Novartis’ MAA868​, an antibody targeting Factor XI and XIa and possible anti-coagulant therapy, to treat thrombotic disorders. The monoclonal antibody (mAb) has the potential to prevent cardiovascular disorders with minimal or no bleeding risk.

“The need for new medicines to treat cardiovascular diseases is clear, and this agreement is part of our strategy to work with innovators outside our walls to advanced medicines that have the potential to have a positive impact for patients,”​ Jay Bradner, president of Novartis Institutes for Biomedical Research, said in a statement.

Novartis and Blackstone to lead

Anthos’ board of directors includes Blackstone and Novartis executives. Jonathan Freeman, senior advisor at Blackstone, will join as chief operating officer. John Glasspool will join Anthos as CEO, after working for Novartis’ cardiovascular franchise for 30 years.

Glasspool stated in a press release that he is looking forward to leading the company as “Anthos is well-positioned to leverage contributions from Blackstone and Novartis to deliver life-saving therapies to patients with cardiovascular disease. We are building a leading cardiovascular company, laser-focused on genetically and pharmacologically validated targets.”

Related news

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us


View more